{"id":"W3189278449","doi":"10.1016/j.eururo.2021.07.019","title":"Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?","year":2021,"lang":"en","type":"editorial","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; Queen's University","funders":"","keywords":"Medicine; Atezolizumab; Nivolumab; Bladder cancer; Adjuvant; Oncology; Internal medicine; Chemotherapy; Neoadjuvant therapy; Immunotherapy; Adjuvant chemotherapy; Cancer; Urology; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000493813,0.0006021212,0.001230796,0.0002586132,0.00008549168,0.0000312807,0.000167801,0.0006337646,0.001854341],"category_scores_gemma":[0.0006989262,0.0005741651,0.0003592077,0.0002028853,0.0001367065,0.00006382652,0.0001829344,0.001045817,0.0006710649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003823079,"about_ca_system_score_gemma":0.001381134,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004753792,"about_ca_topic_score_gemma":0.0002039964,"domain_scores_codex":[0.9964048,0.0004196854,0.0009145669,0.001125323,0.0004492845,0.0006863743],"domain_scores_gemma":[0.9977482,0.0004505239,0.0004048019,0.000742953,0.000472629,0.0001808917],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009914925,0.0003623649,0.00002582613,0.0002267106,0.0005131974,0.0014444,0.0009497831,0.000003630845,0.006889697,0.000002816524,0.9848774,0.003712656],"study_design_scores_gemma":[0.008288651,0.001982597,0.0009281574,0.0004133481,0.0009569096,0.00003828792,0.0000519024,0.00001369897,0.004790901,0.00002891333,0.9820337,0.0004729218],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.008121214,0.01977447,0.0001024386,0.0132735,0.8930158,0.004898462,0.005215325,0.000307403,0.0552914],"genre_scores_gemma":[0.01162488,0.006427152,0.0002734371,0.005460606,0.9303105,0.000593859,0.01137226,0.0006229725,0.03331432],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.03729472,"threshold_uncertainty_score":0.999671,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02389745304614387,"score_gpt":0.3051402551644497,"score_spread":0.2812428021183058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}